Table 1 Characteristics of study participants
Month 20 Booster dose | R3R (RTS,S-boosted) | R3C (RTS,S-unboosted) | C3C (Comparator) | Total |
|---|---|---|---|---|
Total (infants and children) | 241 | 237 | 231 | 709 |
Manhiça, n | 138 | 133 | 128 | 399 |
Bagamoyo, n | 103 | 104 | 103 | 310 |
Infants, n | 59 | 54 | 53 | 166 |
Children, n | 182 | 183 | 178 | 543 |
Month 21, n | 174 | 183 | 170 | 527 |
Month 32, n | 177 | 175 | 177 | 529 |
M21/M32 intersection | 110 | 121 | 116 | 347 |
Agea, median months (IQR) | 27 (2.78) | 26 (2.44) | 27 (2.84) | 26.7 (2.69) |
Female, n (%) | 110 (45.6) | 128 (54.0) | 130 (56.3) | 368 (51.9) |
Anemiab, n (%) | 67 (27.8) | 79 (33.3) | 63 (27.3) | 209 (29.5) |
Malnourishmentc, n (%) | 17 (7.0) | 14 (5.9) | 13 (5.6) | 44 (6.2) |
Previous malariad n (%) | 18 (7.5) | 11 (4.6) | 18 (7.8) | 47 (6.6) |
